Constantine Tam

80PUBLICATIONS
325CO-AUTHORS
Separation technologiesCardiology (incl. cardiovascular diseases)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Language documentation and descriptionPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (80)

|Aug 14, 2026
Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

|Jul 30, 2026
Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States.

|Jul 13, 2026
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.

|Jul 07, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

|Jun 11, 2026
Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.

|Jan 31, 2026
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Mazyar Shadman, Asher Chanan-Khan, David Campbell

Pageof 14

Frequent Collaborators

17 joint publications

John Francis Seymour

13 joint publications

Stephen S Opat

9 joint publications

Jennifer R Brown

9 joint publications

Judith Trotman